Sparrow Pharmaceuticals

About Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cardiometabolic therapeutics to improve outcomes for patients struggling to control type 2 diabetes and related metabolic conditions with current treatment options.

Products & Services

Clofutriben:A highly potent and selective HSD-1 inhibitor in development for type 2 diabetes with elevated cortisol. It is a once-daily oral therapy designed to reduce intracellular cortisol levels and mitigate adverse metabolic effects caused by excess cortisol.

Specialties

Cardiometabolic therapeutics Type 2 diabetes treatment HSD-1 inhibition Precision medicine for metabolic dysfunction

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 95000000 MR: - FA: $95 million FAN: 95000000	D: 2025-09-24 FD: 2025-09-24	5 investors

Series B Latest

2025-09-24

$95.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Robert Jacks

President & Chief Executive Officer

D

David Katz

Chief Scientific Officer

F

Frank Czerwiec

Chief Medical Officer

D

Dora Ferrari

Senior Vice President, Clinical Operations

A

Andre Richer

Vice President, Program Management

J

Jamie MacPherson

Senior Vice President, Regulatory Affairs & Quality Assurance

View 16 more team members with Pro

Unlock Full Team Directory

Recent News